[1. BALMASOVA IP, YUSHCHUK ND, MINBAEV OA, ALLA NR, MALOVA ES, ZHONG JE, SHI Z, GAO CI. Immunopathogenesis of chronic hepatitis. World J. Gastroenterol. 2014, 20, 39, 14156-14171.]Search in Google Scholar
[2. TREPOC CHAN HL, LOK A. Hepatitis B virus infection. Lancet. 2014, 384, 9959, 2053-2063.]Search in Google Scholar
[3. LIU XR, SHEN YH. Membranous glomerulopathy associated with hepatitis B virus infection. HKig Pediatr (newseries), 2002, 13, 22-29.]Search in Google Scholar
[4. VENKATASESHAN VS, LIEBERMAN K, KIM DU, THUNG S, DIUMAN S. Hepatitis B associated glomerulonephritis: pathology, pathogenesis and clinical course. Medicine (Baltimore) 1990, 69, 4, 200-216.10.1097/00005792-199007000-00002]Search in Google Scholar
[5. ZHANG JH, LI ZHOU N. Is there a hepatitis B virus-assocated glomerulonephritis? Identification of HBsAg, HBc and HBcAg with monoclonal antibodies. Chin. Med. J. (Engl)1989, 108, 7, 496-504.]Search in Google Scholar
[6. LIN CY, LIN CS, CHANG GH. Defect of cell mediated immune response against hepatitis;an indication for pathogenesis of hepatitis B virus-associated membranous nephropathy. Nephron 1994 ,765,176-185.10.1159/0001901669200409]Search in Google Scholar
[7. PENG G, Li S, WU W, SUN Z, CHEN Y, CHEN Z. Circulating CD4+CD25+ regulatory T cells correlate with chronic hepatitis B infection. Immunology. 2008, 123, 57-65.]Search in Google Scholar
[8. LU H, ZHU H, ZHOU Y. S gene mutation of HBV in children with HBV-associated glomerulonephritis. Virol. J. 2012, 9, 59, doi 10.IV 86/1743/422Y-9-5.]Search in Google Scholar
[9. HUI D, YAN V, WEI Y, RUIXIZ M, GUANGIU G. Significance of mutations in hepatitis B virus X gene for pathogenesis HBV-associated glomerulonephritis. Acta Virol. 2014, 58, 3, 278-281.]Search in Google Scholar
[10. LAI KH, HO RT, TAM JS, LAI FM. Detection of hepatitis B virus DNA and RNA in kidney of HBV related glomerulonephritis. Kidney Int. 1996, 50, 6, 1965-1997.]Search in Google Scholar
[11. El-SERAQ HR, HAMPEL H, YEH E. RABENECK I. Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology 2002, 36, 6, 1439-1445.10.1002/hep.1840360621]Search in Google Scholar
[12. MOE SM, PAMPALONE A, OFNER S, ROSEMAN M, TED E, HUI SL. Association of hepatitis C virus infection with prevalence and development of kidney diseases. Am J. Kidney Dis 2008, 51, 6, 885-892.10.1053/j.ajkd.2008.03.009247874218440680]Search in Google Scholar
[13. FABRIZI F, MARTIN P, DIXIT V, MESSA P. Hepatitis virus infection and kidney disease: a meta analysis. Clin J. Am Soc Nephrol. 2012, 7, 4, 549-557.]Search in Google Scholar
[14. CHARTER Ed, DUSTIN LB. Hepatitis C virus-induced cryoglobulinaemia. Kidney Int 2009, 76, 8, 818-824.10.1038/ki.2009.247275559819606079]Search in Google Scholar
[15. FABRIZI F, MESSA P, MARTIN P. Novel evidence on hepatitis C virus-associated glomerular disease. Kidney Int. 2014, 86, 3, 466-469.]Search in Google Scholar
[16. TANA MM, HELLER T. Autoantibodies in hepatitis C: red flag or bystander. J Pediat Gastroenterol. Nutr. 2013, 56, 3, 243.]Search in Google Scholar
[17. FERRY S, MURATORI L, LENZI M. HCV and auto immunity. Curr. Pharm. Dis 2008, 14, 1672-1685 (Pub Med).10.2174/13816120878474682418673191]Search in Google Scholar
[18. MARCEAU G, LAPIERRE P, BELAND K, SAUDEYENS H, ALVAREZ F. LKM and autoantibodies in chronic hepatitis C infections. A case of molecular mimicry? Hepatology 2005, 42, 675-682.10.1002/hep.2081616037945]Search in Google Scholar
[19. STOKES MB. Immune complex glomerulonephritis in patients with hepatitis C. Saudi J Kidney Dis Transpl (Serial Online). 2000, 11, 3, 396-404.]Search in Google Scholar
[20. HO V, CHEN J. Hepatitis XC virus associated glomerulonephritis in: PRZONACAR S, An update on glomerulonephritis. Clinical and treatment aspects. 2011. In tech Shanghai, China.10.5772/24800]Search in Google Scholar
[21. ISKANDAR SS, HERRERA GA. Glomerulopathies with organized deposits. Semin Diagn Pathol 2002, 19, 3, 116-132.]Search in Google Scholar
[22. SANSANNO D, LAULETTA G, MONTRONE M, GRANDALIANO G, SCHENA FP, DAMMACCO F. Hepatitis C virus RNA and core protein in kidney glomerular and tubular structures isolated with laser capture microdissection. Clin Exp Immunol 2005, 140, 3, 498-506.10.1111/j.1365-2249.2005.02778.x180938115932511]Search in Google Scholar
[23. CAO Y, ZHANG Y, WANG S, ZOU W. Detection of the hepatitis C virus antigen in kidney tissue from infected patients with various glomerulonephritis. Nephrol Dial Transplant. 2009; 24, 9, 2745-2751.]Search in Google Scholar
[24. KONG D, WU D, VAN T, LI T, ZU S, CHEN F, KIN X, LOU C. Detection of viral antigens in renal tissue of glomerulonephritis patients without serological evidence of hepatitis B virus and hepatitis C virus infection. Int. J. Infect Dis 2013, 17, 7, e 535-e538.10.1016/j.ijid.2013.01.01723474175]Search in Google Scholar
[25. WHO. Hepatitis C. Fact sheet update. April 2014.]Search in Google Scholar
[26. JOHNSON RJ, GRETCH DR, COUSER WG, ALPERS CE, WILSON J, CHUNG N et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl. J. Med 1993, 328, 7, 465-470.10.1056/NEJM1993021832807037678440]Search in Google Scholar
[27. QUARTUCCIO L, SOARDO GE, ROMANO G, SCOTT CA, De MARCHE G et al. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia; efficacy and safety in the absence of steroids. Rheumatology, 2006, 45, 7, 842-846.10.1093/rheumatology/kel00416418196]Search in Google Scholar
[28. HO V, CHEN J. Hepatitis C virus associated glomerulonephritis in: PRABHAKAR SEd. An update on glomerulopathies. Clinical and treatment aspects 2011. In: Tech Shanghai, China.10.5772/24800]Search in Google Scholar
[29. SUGIMOTO K, TAKEI. Clinicopathological features of non-alcoholic fatty liver disease. Hepatol Res 2011, 10, 911-920.10.1111/j.1872-034X.2011.00867.x21951869]Search in Google Scholar
[30. AHN AL, CHOI JK, KIM MN, KIM SA, OH EJ, KUCON HJ, CHO DY. Non-alcoholic fatty liver disease and chronic liver disease in Koreans aged 50 years or older. Korean J. Fam Med. 2013, 34, 3, 199-205.]Search in Google Scholar
[31. SIROTA JC, McFANN K, TARGHER G, CHONCHOL M, JALAL DI. Association between nonalcoholic liver disease and chronic kidney disease: an ultrasound analysis from NHANES 1988-1994. Am J Nephrol. 2012, 36, 5, 466-71. doi: 10.1159/000343885.10.1159/000343885356328723128368]Search in Google Scholar
[32. TARGER G, CHONCHOL M, ZOPPINI G, ABATERUSSO C, DONORA E. Risk of chronic kidney disease in patients with non-alcholic fatty disease. Is there a link ? J Hepatol 2011, 54, 5, 1020-1029.10.1016/j.jhep.2010.11.00721145850]Search in Google Scholar
[33. MUSSO G, GAMBINO R, TABIBIAN JH. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. Plos Med. 2014, 11, 7: e 1001680 doi 10.1374/journal p med 1001680 e collection 2014.]Search in Google Scholar
[34. BULUM T, DUVNJAK L. Relationship between nonalcoholic fatty liver disease markers and renal function in patients with type 1 diabetes. Acta Med Croatia 2011, 65, Supp l, 3, 6-10, Pub Med.]Search in Google Scholar
[35. YILMAZ Y, ALAHDAB Y, YONAL O. Microalbuminuria in non-diabetic patients with nonalcoholic fatty liver disease associated with liver fibrosis. Metabolism 2010, 59, 9, 1327-1330.10.1016/j.metabol.2009.12.01220096896]Search in Google Scholar
[36. ADHIKARI KB, OREN T. Non-alcoholic fatty liver disease (NAFLD) and immune response. J Inst Med 2010, 3, 43-53.10.3126/jiom.v32i3.4960]Search in Google Scholar
[37. IX JH, SHARMA K. Mechanisms linking obesity, chronic kidney disease and fatty liver disease, the role of fetuin A, adiponectin and AMPK. J Am Soc Nephrol 2010, 21, 3, 406-412.10.1681/ASN.2009080820447325420150538]Search in Google Scholar
[38. MOURALIDANE A, SOEDA J, VISCONTI-PUGMIRE, SAMULELSON A, TOMBO J, MARAGKOUDAKI X. Maternal obesity programs offspring non-alcoholic fatty liver disease via innate immune disjunction in mice. Hepatology 2013, 52, 128-138.10.1002/hep.2624823315950]Search in Google Scholar
[39. AMOR J, CHABO C, WAGET A, KLOPP P, VACHOU C, BEMUDEZ-HUNARAN LG. Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes, molecular mechanisms and probiotic treatment. EMBO, Mol Med. 2011, 3, 559-572.]Search in Google Scholar
[40. MELI R, RASO GM, CALIGNANO A. Role of innate response in non-alcoholic fatty liver disease: metabolic complications and therapeutic tools. Front Immunol 2014/doi: 103389/ fimmu 2014-00177.10.3389/fimmu.2014.00177400596524795720]Search in Google Scholar
[41. ORLIC I, MIKOLASEVIC I, BAGIC Z, RACUL S, STIMAC D MILIC. Chronic kidney disease and non-alcoholic liver disease - is there a link? Gastroenterol. Res. Pract. 2014, doi org/10-1155/2014/847539.10.1155/2014/847539396336624729784]Search in Google Scholar
[42. JIN K, NORIS K, VAZIRI ND. Dysregulation of hepatic fatty acid metabolism in chronic kidney disease. Nephrol Dial Transplant. 2013, 28, 2, 313-320.]Search in Google Scholar
[43. YANG M, GONG S, YE SQ, LYMAN B, CHEN P, DY L. Non-alcoholic fatty liver disease in children: focus on nutritional interventions. Nutrients 2014, 6, 1, 4691-4705.10.3390/nu6114691424555725353664]Search in Google Scholar
[44. NEWELL CC. Cirrhotic glomerulonephritis, incidence, morphology, clinical features and pathogenesis. Am. J. Kidney Dis. 1987, 9, 3, 183-190.]Search in Google Scholar
[45. POURIS S, FEEHALLY J. Glomerular IgA deposition in liver disease. Nephrol Dial Transplant, 199, 14, 10, 2279-2282.10.1093/ndt/14.10.227910528642]Search in Google Scholar
[46. TISSANDIE E, MORELLE W, BERTHELOT L, VRTOVSNIK F, DAUGAS M et al. Both IgA nephropathy and alcoholic cirrhosis feature abnormally glycosylated IgA1 and soluble CD89 -IgA complexes common mechanisms for distinct disease. Kidney Int 2011, 80, 12, 1352-1363.10.1038/ki.2011.27621866091]Search in Google Scholar
[47. KALAMBOKIS G, CRISTOU I, STEFANOU D, ARKEUMANI E, TSIANOS EV. Association of liver cirrhosis related IgA nephropathy with portal hypertension. World J Gastroenterol, 2017, 13 13, 43, 5783-5786. 10.3748/wjg.v13.i43.5783417127117963311]Search in Google Scholar